AI Article Synopsis

  • The study aimed to compare COVID-19 patient characteristics, clinical management, and outcomes during the peak (weeks 10-16) and plateau (weeks 17-34) phases of the first pandemic wave in Portugal.
  • A total of 541 adult patients, mostly male with a median age of 65, were analyzed, showing no significant differences in age, initial health scores, and 28-day mortality between the two periods.
  • Key findings indicated fewer comorbidities, higher use of certain treatments (like vasopressors and invasive ventilation) during the peak, whereas the plateau saw increased use of different therapies like remdesivir and corticosteroids and shorter ICU stays.

Article Abstract

Objective: To analyze and compare COVID-19 patient characteristics, clinical management and outcomes between the peak and plateau periods of the first pandemic wave in Portugal.

Methods: This was a multicentric ambispective cohort study including consecutive severe COVID-19 patients between March and August 2020 from 16 Portuguese intensive care units. The peak and plateau periods, respectively, weeks 10 - 16 and 17 - 34, were defined.

Results: Five hundred forty-one adult patients with a median age of 65 [57 - 74] years, mostly male (71.2%), were included. There were no significant differences in median age (p = 0.3), Simplified Acute Physiology Score II (40 versus 39; p = 0.8), partial arterial oxygen pressure/fraction of inspired oxygen ratio (139 versus 136; p = 0.6), antibiotic therapy (57% versus 64%; p = 0.2) at admission, or 28-day mortality (24.4% versus 22.8%; p = 0.7) between the peak and plateau periods. During the peak period, patients had fewer comorbidities (1 [0 - 3] versus 2 [0 - 5]; p = 0.002) and presented a higher use of vasopressors (47% versus 36%; p < 0.001) and invasive mechanical ventilation (58.1 versus 49.2%; p < 0.001) at admission, prone positioning (45% versus 36%; p = 0.04), and hydroxychloroquine (59% versus 10%; p < 0.001) and lopinavir/ritonavir (41% versus 10%; p < 0.001) prescriptions. However, a greater use of high-flow nasal cannulas (5% versus 16%, p < 0.001) on admission, remdesivir (0.3% versus 15%; p < 0.001) and corticosteroid (29% versus 52%, p < 0.001) therapy, and a shorter ICU length of stay (12 days versus 8, p < 0.001) were observed during the plateau.

Conclusion: There were significant changes in patient comorbidities, intensive care unit therapies and length of stay between the peak and plateau periods of the first COVID-19 wave.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9987006PMC
http://dx.doi.org/10.5935/0103-507X.20210037-ptDOI Listing

Publication Analysis

Top Keywords

peak plateau
20
plateau periods
20
versus
14
intensive care
12
periods covid-19
8
cohort study
8
median age
8
versus 36%
8
0001
8
0001 admission
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!